Dr. Ross Cagan
University of Glasgow
cancer biology, drug development, rare genetic diseases
My laboratory works with a variety of collaborators to develop a drug development platform that combines Drosophila genetics with medicinal and computational chemistry. Further, we are using aspects of this platform in a fly-to-bedside trial. Our primary focus is cancer and rare genetic diseases. OOAC would provide an additional bridge between fly and patient by allowing rapid, patient-relevant testing of candidate therapeutics.
We are looking to collaborate with mammalian systems and chemical biologists to develop new therapeutic leads and to explore the biology of cancer therapeutics.